GL Pharm Tech Decides to Absorb Wholly-Owned Subsidiary GL Pharma via Small-Scale Merger with No Share Issuance, No Dilution

GL Pharm Tech decided to absorb its wholly-owned subsidiary GL Pharma on July 31, 2026. The merger is a small-scale merger with no new shares issued, resulting in no dilution for existing shareholders.
The merger ratio is 1:0, so existing shareholders of GL Pharm Tech (including top shareholder W Science with 29.77%) will retain their exact share count and ownership. No change in control.
Purpose: enhance operational efficiency and competitiveness. GL Pharma (pharmaceutical manufacturing and wholesale) will continue as a business division, with no significant impact on financials or operations.
No stock appraisal rights due to small-scale merger. However, if shareholders owning 20% or more of outstanding shares object in writing within 2 weeks of the merger notice, the merger may switch to a normal process.
Post-merger balance sheet: assets 48.8B won, liabilities 28.9B won, equity 19.9B won (based on year-end 2025 consolidated). No change in capital stock.
[AI Comprehensive Analysis]This merger is an internal restructuring of a wholly-owned subsidiary via a no-dilution method, making it a neutral event for shareholders. The key risk to monitor is potential opposition from major shareholders (20%+), which could force a normal merger process.